ClinicalTrials.gg
RecruitingNCT05242835Updated Dec 8, 2025

Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery

An interventional study of Standard duodenal switch and Single-anastomosis duodenal switch in Obesity and Obesity, Morbid, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Laval University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Obesity, Morbid with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Obesity, Morbid · Canada.

Planned enrollment
3rd of 22
151 · median 57
Started
2023
with 1 other
No phase
17 of 32
3 open now
Registered
27th of 32
by date
Lead sponsor
8 of 32
Laval University

Among the 32 studies in Obesity, Morbid with a site in Canada, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2023, is one of 17 with no phase, and was the 27th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

7 of the 32 studies in Obesity, Morbid with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity, Morbid with a site in Canada, or all of them as a file.
02

Study summary

Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question.

Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies.

With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.

03

Conditions studied

  • Obesity
  • Obesity, Morbid

Browse trials for

Keywords

  • Bariatric surgery
04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's planned enrollment of 151 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • had sleeve gastrectomy a minimum of 18 months before
  • still meet the NIH criteria for bariatric surgery (≥35kg/m2 with major comorbidities or BMI≥40kg/m2) or patients with EWL\<50% or significant weight regain (≥20%EWL)

Exclusion criteria

Exclusion Criteria:

  • general for bariatric surgery
  • \<35kg/m2
  • pregnancy
  • cirrhosis
  • abnormal bowel habits including irritable bowel syndrome and inflammatory bowel disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
151 participants (estimated)

Study arms

  • Active comparator
    biliopancreatic diversion with duodenal switch

    Patient randomized for a the standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)

    Procedure: Standard duodenal switch

  • Experimental
    Single-anastomosis duodeno-ileal anastomosis

    Patient randomized for a single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)

    Procedure: Single-anastomosis duodenal switch

Interventions

  • ProcedureStandard duodenal switch

    Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)

    Also known as: BPD-DS

  • ProcedureSingle-anastomosis duodenal switch

    Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)

    Also known as: SADI

07

What researchers measure

Primary outcomes

  1. Excess weight loss

    Percentage of excess weight loss mobilized in response to surgery

    Time frame: 12 month

Secondary outcomes

  1. Peroperative complications

    Complications graded with Clavien classification

    Time frame: from baseline up to 60 months

  2. Risk of malnutrition

    Risk of malnutrition assessed through measurement of its risk being mild (albumin\<35g\\L), moderate (albumin\<30g/L) or severe (albumin\<25g/L)

    Time frame: from baseline to 60 months

  3. Change in quality of life (SF-36)

    36-item short form survey evaluating quality of life on a scale form 0 to 100

    Time frame: from baseline to 60 months

  4. Change in quality of life (BAROS)

    Bariatric Analyses and Reporting Outcomes System score form -7 to 9

    Time frame: from baseline to 60 months

  5. Change in quality of life (QLaval)

    Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7

    Time frame: from baseline to 60 months

  6. Gastro-intestinal side effects

    Evaluation of gastro-intestinal side effects with the Gastro-Intestinal Quality of Life Index from 0 to 144

    Time frame: from baseline to 60 months

  7. Change in nutritional status (calcium)

    Change in nutritional status based on blood analysis of calcium (mmol/L)

    Time frame: from baseline to 60 months

  8. Change in nutritional status (ferritin)

    Change in nutritional status based on blood analysis of ferritin (ug/L)

    Time frame: from baseline to 60 months

  9. Change in nutritional status (TIBC)

    Change in nutritional status based on blood analysis of TIBC (umol/L)

    Time frame: from baseline to 60 months

  10. Change in nutritional status (iron)

    Change in nutritional status based on blood analysis of iron (umol/L)

    Time frame: from baseline to 60 months

  11. Change in nutritional status (prealbumin)

    Change in nutritional status based on blood analysis of prealbumin (g/L)

    Time frame: from baseline to 60 months

  12. Change in nutritional status (transferrin)

    Change in nutritional status based on blood analysis transferrin (g/L)

    Time frame: from baseline to 60 months

  13. Change in nutritional status (vitamin A)

    Change in nutritional status based on blood analysis of vitamin A (umol/L)

    Time frame: from baseline to 60 months

  14. Change in nutritional status (vitamin D3)

    Change in nutritional status based on blood analysis of vitamin D3 (nmol/L)

    Time frame: from baseline to 60 months

  15. Change in nutritional status (parathormone)

    Change in nutritional status based on blood analysis parathormone (ng/L)

    Time frame: from baseline to 60 months

  16. Change in food intake

    Evaluation of the change in food intake using a web-based food frequency questionnaire (kcal/day)

    Time frame: from baseline to 60 months

  17. Change in eating behavior

    Change of eating behavior using the Three-Factor Eating Questionnaire evaluating cognitive restraint of eating on a scale from 0 to 20, disinhibition on a scale from 0 to 16 and hunger on a scale from 0 to 15

    Time frame: from baseline to 60 months

  18. Change in food addiction

    Change of eating behavior using the Yale Food Addiction Scale that includes a "symptom count" scale from 0 to 7 reflecting the number of addiction-like criteria endorsed and a dichotomous evaluation that indicates whether a threshold of three or more "symptoms" plus clinically significant impairment or distress has been met

    Time frame: from baseline to 60 months

  19. Change in binge eating behavior

    Change of eating behavior using the Binge Eating scale from 0 to 46

    Time frame: from baseline to 60 months

  20. Evolution of obesity related diseases

    Remission rate for comorbidities, including T2D, hypertension, dyslipidemia, sleep apnea according to the ASMBS definition of outcomes reporting

    Time frame: from baseline to 60 months

08

Study locations

1 of 1 sites recruiting
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec
    Québec, Quebec G1V 4G5, Canada
    Recruiting
    • Suzy Laroche · Contactsuzy_laroche@ssss.gouv.qc.ca · 418-656-8711
    • Laurent Biertho, MD · Principal investigator
    • André Tchernof, PhD · Sub investigator
    • Caroline Diorio, PhD · Sub investigator
    • Andreanne Michaud, PhD · Sub investigator
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jan 2027, 47 months after the start.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 47 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2022
First posted
Feb 16, 2022
StartActual
Feb 3, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05242835
Lead sponsor
Laval University
Collaborators
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Laurent Biertho (Principal Investigator, Laval University) — Principal investigator
First posted
Feb 16, 2022
Start date
Feb 3, 2023
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Dec 8, 2025

Study contacts

Mélanie Nadeau, MSc
Contact
melanie.nadeau@criucpq.ulaval.ca
418-656-8711 ext. 3490
Suzy Laroche
Contact
suzy_laroche@ssss.gouv.qc.ca
418-656-8711 ext. 3841
Laurent Biertho, MD
principal investigator · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion